Distilling complexity to advance cardiac tissue engineering

Affiliations

¹ Department of Biomedical Engineering, Stem Cell Institute, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
² Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
³ Harvard Medical School and Harvard Stem Cell Institute, Boston, MA 02114, USA.
⁴ Department of Cardiothoracic Surgery, Stanford University, Stanford, CA 94305, USA. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA.
⁵ Department of Cardiovascular Surgery, INSERM U 970, Hôpital Européen Georges Pompidou and University Paris Descartes, 75006 Paris, France.
⁶ Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, Departments of Pathology, Bioengineering, and Medicine, University of Washington, Seattle, WA 98109, USA.
⁷ Departments of Mechanical Engineering and, by courtesy, Molecular and Cellular Physiology and Bioengineering, Stanford University, Stanford, CA 94305, USA.
⁸ Institute of Biomaterials and Biomedical Engineering, Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario M5S 3G9, Canada.
⁹ Stanford Cardiovascular Institute and Departments of Medicine and Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
¹⁰ Departments of Medicine and Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
¹¹ Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
¹² Institute of Pharmacology and Toxicology, University Medical Center, Georg-August University Göttingen and DZHK (German Center for Cardiovascular Research), partner site Göttingen, 37075 Göttingen, Germany.
¹³ Departments of Biomedical Engineering and Medicine, Columbia University, New York, NY 10032, USA. gv2131@columbia.edu.

PMID: 27280684
PMCID: PMC4959426
DOI: 10.1126/scitranslmed.aad2304

Review

Distilling complexity to advance cardiac tissue engineering

Brenda M Ogle et al. Sci Transl Med. 2016.

. 2016 Jun 8;8(342):342ps13.

doi: 10.1126/scitranslmed.aad2304.

Authors

Affiliations

¹ Department of Biomedical Engineering, Stem Cell Institute, Masonic Cancer Center, University of Minnesota, Minneapolis, MN 55455, USA.
² Department of Biomedical Engineering, Duke University, Durham, NC 27708, USA.
³ Harvard Medical School and Harvard Stem Cell Institute, Boston, MA 02114, USA.
⁴ Department of Cardiothoracic Surgery, Stanford University, Stanford, CA 94305, USA. Veterans Affairs Palo Alto Health Care System, Palo Alto, CA 94304, USA.
⁵ Department of Cardiovascular Surgery, INSERM U 970, Hôpital Européen Georges Pompidou and University Paris Descartes, 75006 Paris, France.
⁶ Center for Cardiovascular Biology, Institute for Stem Cell and Regenerative Medicine, Departments of Pathology, Bioengineering, and Medicine, University of Washington, Seattle, WA 98109, USA.
⁷ Departments of Mechanical Engineering and, by courtesy, Molecular and Cellular Physiology and Bioengineering, Stanford University, Stanford, CA 94305, USA.
⁸ Institute of Biomaterials and Biomedical Engineering, Department of Chemical Engineering and Applied Chemistry, University of Toronto, Toronto, Ontario M5S 3G9, Canada.
⁹ Stanford Cardiovascular Institute and Departments of Medicine and Radiology, Stanford University School of Medicine, Stanford, CA 94305, USA.
¹⁰ Departments of Medicine and Pediatrics, Stanford University School of Medicine, Stanford, CA 94305, USA.
¹¹ Department of Biomedical Engineering, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
¹² Institute of Pharmacology and Toxicology, University Medical Center, Georg-August University Göttingen and DZHK (German Center for Cardiovascular Research), partner site Göttingen, 37075 Göttingen, Germany.
¹³ Departments of Biomedical Engineering and Medicine, Columbia University, New York, NY 10032, USA. gv2131@columbia.edu.

PMID: 27280684
PMCID: PMC4959426
DOI: 10.1126/scitranslmed.aad2304

Abstract

The promise of cardiac tissue engineering is in the ability to recapitulate in vitro the functional aspects of a healthy heart and disease pathology as well as to design replacement muscle for clinical therapy. Parts of this promise have been realized; others have not. In a meeting of scientists in this field, five central challenges or "big questions" were articulated that, if addressed, could substantially advance the current state of the art in modeling heart disease and realizing heart repair.

PubMed Disclaimer

Figures

**Fig. 1. Microtissue platforms: Achieving complexity on a small scale**
Microtissue platforms, also called “organs-on-a-chip”, are likely to be transformative to drug testing, modeling of cardiac disease, and implementation of personalized medicine. The impact of these technologies likely will be translated sooner than clinical applications, because of the simpler tissue engineering and regulatory requirements.

**Fig. 2. Tissue-engineered heart repair**
Major progress is being made in translational studies of various types of engineered cardiac patches for implantation. An IGF-1–loaded fibrin patch markedly enhances the effects of iPSC-derived cells in a swine model of ischemia-reperfusion. Modified from (33), with permission.

**Fig. 3. A map of heart repair**
Among variety of tissue-engineering systems currently under investigation, the best options for clinical translation are found in a Venn diagram between the biological complexity, feasibility, and safety and efficacy for the patient.

See this image and copyright information in PMC

References

1. Coulombe KL, Bajpai VK, Andreadis ST, Murry CE. Heart regeneration with engineered myocardial tissue. Annu Rev Biomed Eng. 2014;16:1–28. - PMC - PubMed
1. Menasche P, Vanneaux V, Hagege A, Bel A, Cholley B, Cacciapuoti I, Parouchev A, Benhamouda N, Tachdjian G, Tosca L, Trouvin JH, Fabreguettes JR, Bellamy V, Guillemain R, Suberbielle Boissel C, Tartour E, Desnos M, Larghero J. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J. 2015;36:2011–2017. - PubMed
1. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32:760–772. - PubMed
1. Cimetta E, Godier-Furnemont A, Vunjak-Novakovic G. Bioengineering heart tissue for in vitro testing. Curr Opin Biotechnol. 2013;24:926–932. - PMC - PubMed
1. Mathur A, Loskill P, Shao K, Huebsch N, Hong S, Marcus SG, Marks N, Mandegar M, Conklin BR, Lee LP, Healy KE. Human iPSC-based cardiac microphysiological system for drug screening applications. Scientific reports. 2015;5:8883. - PMC - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

LinkOut - more resources

Full Text Sources
Other Literature Sources
- The Lens - Patent Citations Database
- scite Smart Citations

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Distilling complexity to advance cardiac tissue engineering

Affiliations

Distilling complexity to advance cardiac tissue engineering

Authors

Affiliations

Abstract

Figures

References

Publication types

MeSH terms

Grants and funding

LinkOut - more resources

Full Text Sources

Other Literature Sources